Real-World Safety and Clinical Response of Janus Kinase Inhibitor Upadacitinib in the Treatment of Hidradenitis Suppurativa: A Retrospective Cohort Study
Published: 25 July 2022| Version 1 | DOI: 10.17632/fjv74v2w65.1
Contributor:
John Frew
Description
Real-World Safety and Clinical Response of Janus Kinase Inhibitor Upadacitinib in the Treatment of Hidradenitis Suppurativa: A Retrospective Cohort Study - JAAD 2022
Files
Categories
Dermatology, Hidradenitis Suppurativa, Janus Kinase